Akers Biosciences OxiCheck Study Results Positive, Stock Up
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:21AM CDT
Akers Biosciences Inc. (AKER) recently announced favorable clinical results for its BreathScan OxiCheck disposable breath test.
CAH: 79.67 (-0.05), QDEL: 21.77 (+0.03), AKER: 3.58 (-0.10), NUVA: 65.47 (unch)
Akers Biosciences (AKER) Q2 Loss Narrows Y/Y, Stock Gains
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:16AM CDT
Shares of Akers Biosciences increased almost 3% to close at $3.17 on Aug 11, after the company reported second-quarter 2016 results.
BAX: 46.73 (-0.16), QDEL: 21.77 (+0.03), AKER: 3.58 (-0.10), NUVA: 65.47 (unch)
Akers Biosciences (AKER) Revenues Surge in Q2 Earnings
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 7:26AM CDT
Akers Biosciences Inc. (AKER) reported second-quarter product revenues of $$956,486, which increased 28% from the year-ago quarter.
AKER: 3.58 (-0.10)
Akers Biosciences Announces H1 and Q2 2016 Earnings
Marketwire Canada - Thu Aug 11, 6:00AM CDT
Sales of Flagship Rapid HIT Test +68% Over H1 2015 and +57% Over Q2 2015; Conference Call Scheduled for 9:00 a.m. Eastern Time Today
AKER: 3.58 (-0.10)
Akers Biosciences Announces Conference Call to Discuss Q2 2016 Earnings
Marketwired - Tue Aug 09, 10:00AM CDT
THOROFARE, NJ--(Marketwired - Aug 9, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"
AKER: 3.58 (-0.10)
Akers Biosciences to Present at LD Micro Invitational Conference
Marketwire Canada - Fri Jun 03, 8:52AM CDT
THOROFARE, NJ--(Marketwired - Jun 3, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L) (the "Company"
AKER: 3.58 (-0.10)
Akers (AKER) Reports Q1 Earnings; Product Revenue Up 79.3%
Aparajita Dutta - Zacks Investment Research - Thu May 12, 7:46AM CDT
Akers' (AKER) first-quarter product revenue increased 79.3% from the year-ago quarter to $738,023
AKER: 3.58 (-0.10)
Akers Biosciences Reports Earnings for Q1 2016
Marketwire Canada - Thu May 12, 6:00AM CDT
PIFA Heparin/PF4 Rapid Tests Sales Up 88%; Total Revenues up 45%
AKER: 3.58 (-0.10), AKR: 36.94 (+0.25)
Akers Biosciences (AKER) Q1 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:52AM CDT
Akers Biosciences Inc (AKER) is expected to report first-quarter 2016 results on May 12.
CAPR: 3.66 (+0.06), STAA: 8.78 (-0.16), AKER: 3.58 (-0.10), VBLT: 4.11 (+0.08)
Akers Biosciences to Present at 'Pioneers 2016' Investor Conference
Marketwire Canada - Wed May 04, 1:00PM CDT
THOROFARE, NJ--(Marketwired - May 4, 2016) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR), (the "Company"
AKER: 3.58 (-0.10), AKR: 36.94 (+0.25)
Akers Board Rearrangement
Marketwired - Fri Apr 29, 6:01AM CDT
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"
AKER: 3.58 (-0.10)
Akers' Loss Widens in 2015, Revenues Deteriorate Y/Y
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 9:46AM CDT
Akers Biosciences Inc. (AKER) reported loss of $1.81 per share in full-year 2015, much wider than 66 cents recorded in 2014.
AMZN: 769.16 (+1.58), BAX: 46.73 (-0.16), AKER: 3.58 (-0.10), HRC: 59.31 (-0.21)
Akers Biosciences Reports Earnings for Fiscal Year 2015
Marketwired - Wed Mar 30, 6:00AM CDT
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L) ("Akers Bio" or the "Company"
AKER: 3.58 (-0.10)